John Wahren
Chief Tech/Sci/R&D Officer en Creative Peptides Sweden AB .
Perfil
John Wahren was the founder of Cebix, Inc. which was founded in 2008, where he held the title of Director & Chief Scientific Officer from 2010 to 2014.
He is currently employed as an Emeritus Professor-Clinical Physiology at Karolinska Institutet and as Chief Scientific Officer at Creative Peptides Sweden AB.
Dr. Wahren's former position was as a Professor at the University of Lausanne in 1984.
He obtained his doctorate degree from Karolinska Institutet.
Cargos activos de John Wahren
| Empresas | Cargo | Inicio |
|---|---|---|
Creative Peptides Sweden AB
 Creative Peptides Sweden AB Pharmaceuticals: MajorHealth Technology Creative Peptides Sweden AB develops and manufactures drugs. The company discovers and develops biopharmaceutical drugs to treat complications of Type 1 diabetes. It was founded in 1996 and is headquartered in Stockholm, Sweden. | Chief Tech/Sci/R&D Officer | - |
| Karolinska Institutet | Corporate Officer/Principal | 24/06/2009 |
Antiguos cargos conocidos de John Wahren.
| Empresas | Cargo | Fin |
|---|---|---|
| University of Lausanne | Corporate Officer/Principal | 01/01/1984 |
Cebix, Inc.
 Cebix, Inc. Pharmaceuticals: MajorHealth Technology Cebix, Inc. provided treatments for complications of diabetes. It developed Ersatta, a proprietary disease-modifying replacement peptide for the treatment of complications associated with diabetes, including diabetic peripheral neuropathy, autonomic neuropathy, nephropathy, and retinopathy. The company was founded by John Wahren and Lars G. Ekman in 2008 and was headquartered in San Diego, CA. | Founder | - |
Formación de John Wahren.
| Karolinska Institutet | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 2 |
|---|---|
Cebix, Inc.
Cebix, Inc. Pharmaceuticals: MajorHealth Technology Cebix, Inc. provided treatments for complications of diabetes. It developed Ersatta, a proprietary disease-modifying replacement peptide for the treatment of complications associated with diabetes, including diabetic peripheral neuropathy, autonomic neuropathy, nephropathy, and retinopathy. The company was founded by John Wahren and Lars G. Ekman in 2008 and was headquartered in San Diego, CA. | Health Technology |
Creative Peptides Sweden AB
Creative Peptides Sweden AB Pharmaceuticals: MajorHealth Technology Creative Peptides Sweden AB develops and manufactures drugs. The company discovers and develops biopharmaceutical drugs to treat complications of Type 1 diabetes. It was founded in 1996 and is headquartered in Stockholm, Sweden. | Health Technology |
- Bolsa de valores
- Insiders
- John Wahren
